King Pharmaceuticals KG Legacy Reinsurance — Underwriting Income Loss Net

Similar metrics at other companies

EGLegacy — Underwriting Income (Loss)

-$22M-57.1%

AXSReinsurance — Underwriting Income Loss Net

$30.01M+3.8%

SPNTReinsurance — Underwriting Income (Loss)

$40.8M+386%

EGLegacy — Net written premiums

$89M-83.9%

ACGLReinsurance — Underwriting Income Loss Segment

$441M+164%

CBGlobal Reinsurance — Underwriting Income (Loss)

$78M+388%

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-67.6%

Enterprise value$184.93M-50.0%

P/E1.2×—

P/S1.6×-24.3×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept kg:UnderwritingIncomeLossNet.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's legacy reinsurance — underwriting income loss net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's legacy reinsurance — underwriting income loss net?: King Pharmaceuticals (KG) reported legacy reinsurance — underwriting income loss net of -$3.28M in Q1 2026.
What does legacy reinsurance — underwriting income loss net mean?: Calculated as net premiums earned minus net losses, loss adjustment expenses, and underwriting expenses. This is the primary measure of the core profitability of the legacy reinsurance segment's underwriting activities.